An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

Annals of Hematology, Supplement

Volumn 84, Issue 13, 2005, Pages 9-17

  Wijermans, P W ^a   Lubbert M ^b   Verhoef, G ^c   Klimek, V ^d   Bosly, A ^e  

^a LEYENBURG HOSPITAL   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ACL Mont Godinne ^*  (Belgium)

Author keywords

Decitabine; Epigenetic therapy; Myelodysplastic syndrome (MDS); Risk factor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; LIVER ENZYME; AZACITIDINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; DNA; CREATININE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LEUKEMIA; ADULT; AGE; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHROMOSOME ABERRATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; ENZYME BLOOD LEVEL; EPIGENETICS; FEMALE; HEADACHE; HEARING IMPAIRMENT; HEART ATRIUM FIBRILLATION; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; DRUG ANTAGONISM; DRUG EFFECT; EUROPE; GENETIC EPIGENESIS; GENETICS; KAPLAN MEIER METHOD; META ANALYSIS; MIDDLE AGED; REMISSION; AGE DISTRIBUTION; CANCER CLASSIFICATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DEMETHYLATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; GENDER; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MULTIPLE CYCLE TREATMENT; MYELOBLAST; NEUTROPHIL COUNT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHARMACOGENETICS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; UNITED STATES; BLAST CELL; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER REGRESSION; CHROMOSOME ANALYSIS; CREATININE BLOOD LEVEL; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; GERIATRIC PATIENT; HEMOGLOBIN BLOOD LEVEL; OUTCOME ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; EUROPE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION;

EID: 29144473297     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0012-1     Document Type: Article

References (18)

1. Aoki E, Uchida T, Ohashi H, Murase T, Ichikawa A, Yamao K, Hotta T, Kinoshita T, Saito H, Murate T (2000) Methylation status of the p15ink4b gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndrome. Leukemia 14:586-593 10.1038/sj.leu.2401719
2. Bennet JM, Catovskty D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 74:395-408
3. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte T, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg P (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674 11090046
4. Cheson BD, Jaspern DM, Simon R, Friedman MA (1986) A critical appraisal of low dose cytosine arabinoside in patients with acute non lymphocytic leukaemia and myelodysplastic syndrome. J Clin Oncol 4:1857-1864 3537219
5. Christman JK (2002) 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21:5483-5495 10.1038/ sj.onc.1205699
6. Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21:5380-5387 10.1038/sj.onc.1205598
7. Daskalakis M, Nguyen TT, Nguyen C, Goldberg P, Ko G, Wijermaqns P, Jones PA, Lübbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964 10.1182/blood.V100.8.2957
8. Erratum (1998) Blood 91:1100
9. Greenberg P, Cox C, Le Bau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashi K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 9058730
10. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R, FDA (2005) Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604-3608 10.1158/1078-0432.CCR-04-2135
11. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B Study. J Clin Oncol 15:2441-2452 10.1200/JCO.2002.04.044
12. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287-1292 10.1200/ JCO.2004.08.082
13. Lübbert M, Wijermans P, Kunzman R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high risk myelodysplastic syndrome following low dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:1-11 10.1046/j.1365-2141.2001.03020.x
14. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ, Kyungmann K (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndrome: A phase III intergroup study. Ann Hematol 65:162-168 10.1007/BF01703109
15. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15ink4b gene in myelodysplastic syndrome is frequent and acquired during disease progression. Blood 91:2985-2990 9531610
16. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JM (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440 10.1200/ JCO.2002.04.117
17. Wijermans PW, Krulder JWM, Huijgens PC, Neve P (1997) Continuous infusion of low dose 5-aza-2′-deoxycytidine in elderly patients with high risk myelodysplastic syndrome. Leukemia 11:1-5 10.1038/ sj.leu.2400526
18. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2002) Low dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962